US2016066551A1PendingUtilityA1

Non human animal model for ulcerative colitis and its main complications

Assignee: OGIER-DENIS ERICPriority: Apr 13, 2011Filed: Nov 17, 2015Published: Mar 10, 2016

Est. expiryApr 13, 2031(~4.7 yrs left)· nominal 20-yr term from priority

Inventors:Eric Ogier-Denis Xavier Treton Fanny Daniel Cecile Guichard Eric Pedruzzi Yoram Bouhnik Yann Harnoy

A61P 43/00A01K 2267/0325A61K 31/155A01K 67/02A61K 31/429A61K 31/47A61P 1/04C12N 15/8509A01K 2227/10C12N 2015/8527A01K 2227/105C12Q 1/6876A01K 2267/03A01K 67/0276A01K 2217/15A61K 49/0008

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal.

Claims

exact text as granted — not AI-modified

1 . A transgenic non human animal model for ulcerative colitis and its main complications comprising a targeted disruption in the Interleukin 10 (IL10) and NADPH-oxidasel (NOX1) genes so that IL10 and NOX1 are not expressed in said animal. 
     
     
         2 . The transgenic non human animal model according to  claim 1  which is knock-out for IL-10 and NOX1. 
     
     
         3 . The transgenic non human model according to  claim 1  which is a rodent. 
     
     
         4 . The transgenic non human model according to  claim 1 , wherein an appendectomy or a caecal floor removing was performed on the animal. 
     
     
         5 . A method for producing a transgenic non human animal model for ulcerative colitis and its main complications, comprising cross-breeding a knock-out animal for IL10 with a knock-out animal for NOX1. 
     
     
         6 - 7 . (canceled) 
     
     
         8 . The transgenic non human animal model of  claim 1 , wherein said main complications include primary sclerosing cholangitis and colorectal cancer. 
     
     
         9 . The transgenic non human animal model of  claim 3 , wherein said rodent is a mouse or a rat.

Join the waitlist — get patent alerts

Track US2016066551A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.